Reckamp K - Search Results

1

Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.

Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, Zhang C, Liang W, Scuto A, Weng S, Morosini D, Cao ZA, Zinda M, Figlin R, Huszar D, Jove R, Yu H. Xin H, et al. Among authors: reckamp k. Cancer Res. 2011 Nov 1;71(21):6601-10. doi: 10.1158/0008-5472.CAN-11-1217. Epub 2011 Sep 15. Cancer Res. 2011. PMID: 21920898 Free PMC article.

2

Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.

Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM. Sharma S, et al. Among authors: reckamp k. Cancer Res. 2005 Jun 15;65(12):5211-20. doi: 10.1158/0008-5472.CAN-05-0141. Cancer Res. 2005. PMID: 15958566

3

Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.

Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, Dubinett SM. Krysan K, et al. Among authors: reckamp kl. Cancer Res. 2005 Jul 15;65(14):6275-81. doi: 10.1158/0008-5472.CAN-05-0216. Cancer Res. 2005. PMID: 16024629

4

The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma.

Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. Mestas J, et al. Among authors: reckamp k. J Immunol. 2005 Oct 15;175(8):5351-7. doi: 10.4049/jimmunol.175.8.5351. J Immunol. 2005. PMID: 16210641

5

A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.

Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA. Reckamp KL, et al. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3381-8. doi: 10.1158/1078-0432.CCR-06-0112. Clin Cancer Res. 2006. PMID: 16740761 Clinical Trial.

6

Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy.

Reckamp KL, Figlin RA, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, Strieter RM. Reckamp KL, et al. J Immunother. 2007 May-Jun;30(4):417-24. doi: 10.1097/CJI.0b013e31802e089a. J Immunother. 2007. PMID: 17457216

7

Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.

Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM. Reckamp KL, et al. J Thorac Oncol. 2008 Feb;3(2):117-24. doi: 10.1097/JTO.0b013e3181622bef. J Thorac Oncol. 2008. PMID: 18303430 Free article. Clinical Trial.

8

Chemokines as therapeutic targets in renal cell carcinoma.

Reckamp KL, Strieter RM, Figlin RA. Reckamp KL, et al. Expert Rev Anticancer Ther. 2008 Jun;8(6):887-93. doi: 10.1586/14737140.8.6.887. Expert Rev Anticancer Ther. 2008. PMID: 18533798 Free PMC article. Review.

9

NCCN Task Force Report: mTOR inhibition in solid tumors.

Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB 3rd, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ Jr, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. Figlin RA, et al. Among authors: reckamp k. J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-20; quiz S21-2. J Natl Compr Canc Netw. 2008. PMID: 18926092 Review.

10

The role of targeting mammalian target of rapamycin in lung cancer.

Pal SK, Figlin RA, Reckamp KL. Pal SK, et al. Clin Lung Cancer. 2008 Nov;9(6):340-5. doi: 10.3816/CLC.2008.n.049. Clin Lung Cancer. 2008. PMID: 19073516 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

181 results

Search Page